Our History

Building For a Transformative Future

From our start in Beijing in 2010, with a handful of entrepreneurial scientists and developers…

…to today, with a global team across five continents, including over 1,000 in the United States and hundreds in Europe and Australia, driving a rich pipeline and high-value commercial medicines…

…we are united by a shared passion for discovering and developing potential new medicines and improving access to them.

And we’re just getting started.

2010

2010

2010

Founded as a research and development company

2011

2011

2011

Initiated discovery programs at our first R&D center, in Beijing

2012

2012

2012

Initiated PD-1 and BTK discovery programs

2013

2013

2013

Started first clinical development in Australia

2014

2014

2014

Began clinical development of pamiparib and zanubrutinib

2015

2015

2015

Opened first U.S. office (Massachusetts)

2016

2016

2016

Completed Nasdaq IPO

2017

2020

2017

Became a commercial-stage company in China with medicines in-licensed from Celgene (now part of BMS); initiated the first global Phase 3 registrational trial of zanubrutinib; completed construction of first manufacturing facility in Suzhou, China

2018

2017

2018

Completed dual primary listing on the Hong Kong Stock Exchange; established presence in Europe; secured our first China national reimbursement

2019

2018

2019

Received first global approval, in the U.S., for BRUKINSA® (zanubrutinib); received first global approval, in China, for tislelizumab; entered global strategic collaboration with Amgen; completed first biologics manufacturing plant in Guangzhou, China

2020

2019

2020

Received first approvals for BRUKINSA® in China; received additional approvals in China for tislelizumab; secured national reimbursement in China for tislelizumab, BRUKINSA®, and an in-licensed medicine; established additional R&D center in Shanghai

2021

2021

2021

Entered global strategic collaborations with Novartis for tislelizumab and ociperlimab; received approvals in the U.S. for additional indications of BRUKINSA®’s; received first approval in the EU and UK for BRUKINSA®; acquired a 42-acre site near Princeton, N.J. for a biologics manufacturing plant and clinical R&D center; completed third stock exchange listing, on the STAR Market of the Shanghai Stock Exchange